IP Library Granted Patent US 7,553,823
Granted Patent B2
US 7,553,823 · App. 11/522,120 · Granted Jun 30, 2009

C-pyrazole A2A receptor agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,553,823
App. No.
11/522,120
Granted
Jun 30, 2009
Kind
B2
Abstract

2-adenosine C-pyrazole compounds having formula (a) and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Claims (12)

1. A compound having the formula:

wherein R 1 is —CH 2 OH;

R 2 is independently selected from the group consisting of hydrogen, C 1-10 alkyl and aryl, wherein the alkyl and aryl substituents are optionally substituted with from 1 to 2 substituents independently selected from the group consisting of halo, OR 20 , aryl, CF 3 , and CN, and wherein each optional aryl substituent is optionally substituted with halo, alkyl, CF 3 and CN;

R 3 and R 4 are each individually selected from the group consisting of hydrogen, methyl, and halo; and

R 20 is selected from H, and C 1-6 alkyl.

2. A method for stimulating coronary vasodilatation in a mammal by administering to the mammal a therapeutically effective amount of a compound of claim 1 that is sufficient to stress the heart and induce a coronary steal situation for the purposes of imaging the heart.

3. The method of claim 2 wherein the therapeutically effective amount ranges from about 0.01 to about 100 mg/kg weight of the mammal.

4. The method of claim 2 wherein the mammal is a human.

5. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutical excipients.

6. The pharmaceutical composition of claim 5 wherein the pharmaceutical composition is in the form of a solution.

7. The pharmaceutical composition of claim 6 wherein the solution is formulated for injection.

8. The pharmaceutical composition of claim 5 wherein the composition is useful as an anti-inflammatory, in adjunctive therapy with angioplasty, as a platelet aggregation inhibitor, and as an inhibitor of platelet and neutrophil activation.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2011
From: GILEAD PALO ALTO, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 026424/0925 →
MERGER Recorded Aug 10, 2010
From: APEX MERGER SUB, INC.; CV THERAPEUTICS, INC.
To: GILEAD PALO ALTO, INC.
Reel/Frame 024812/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2010
From: TPG-AXON ROYALTY TRUST
To: TPG-AXON LEX SUB-TRUST
Reel/Frame 023731/0916 →
MERGER Recorded Oct 6, 2009
From: GILEAD PALO ALTO, INC.
To: TPG-AXON ROYALTY TRUST
Reel/Frame 023330/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2009
From: ZABLOCKI, JEFF A.; PALLE, VENKATA P.; ELZEIN, ELFATIH O.
To: CV THERAPEUTICS, INC.
Reel/Frame 022364/0422 →
SECURITY AGREEMENT Recorded Apr 16, 2008
From: CV THERAPEUTICS, INC.
To: TPG-AXON ROYALTY TRUST
Reel/Frame 020808/0823 →